Autoinjectors Market by Usage (Disposable, Reusable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Obesity, Anaphypaxis, Multiple Sclerosis), Route of Administration (SC, IM), Volume (<3ml, >3ml) - Global Forecast to 2030
The global autoinjectors market is projected to to expand to a value of USD 3.02 billion in 2030 from USD 1.40 billion in 2024, with a significant CAGR of 13.6%. The autoinjector finished formulati... もっと見る
日本語のページは自動翻訳を利用し作成しています。
SummaryThe global autoinjectors market is projected to to expand to a value of USD 3.02 billion in 2030 from USD 1.40 billion in 2024, with a significant CAGR of 13.6%. The autoinjector finished formulations market is projected to surge to a value of USD 134.27 billion in 2030 from USD 67.30 billion in 2024, growing at a CAGR of 12.2%.Favorable reimbursement policies in North America and Europe coupled with launch of biosimilars across the globe are some of the factors contributing towards the market growth. “The manual autoinjectors segment accounted for the largest share in 2023.” On the basis of technology, the autoinjectors market is further segmented into manual, and automatic. The manual autoinjectors segment dominated the market in 2023, owing to the rise in demand due to rising incidence of conditions such as diabetes, multiple sclerosis, and rheumatoid arthritis. Furthermore, cost-effectiveness and expanding new therapeutic applications, is likely to increase their overall market potential for manual autoinjectors in coming years. “By end user, the home care settings segment accounted for the largest share in the autoinjectors market.” The end user segment in the autoinjectors market is segmented into home care settings, hospitals & clinics, and ambulatory care settings. In 2023, the home care settings segment accounted for the largest share owing to increased adoption of autoinjectors at home care settings. Furthermore, cost effectiveness, launch of user friendly autoinjector devices is likely to boost the growth of the home care settings segment. Use of autoinjectors for emergency situations such as anaphylactic reactions is likely to increase demand for autoinjectors in hospitals & clinics further propelling the growth of the market. “North America: the largest share of the autoinjectors market” North America dominated the autoinjectors market in 2023 and likely continue dominance during the forecast period. Well-developed healthcare infrastructure, prevalence of chronic diseases such as diabetes, rheumatoid arthritis, and multiple sclerosis and favourable reimbursement policies in North America are some of the factors influencing the use of autoinjectors subsequently contributing towards market growth. The Asia Pacific autoinjectors market is predicted to grow at the significant CAGR during the forecast period of 2024-2030. The growth of the region is primarily attributed to the presence of large number of pharmaceutical and biopharmaceutical companies and growing number of regulatory apporvals for autoinjectors in the region especially China, India and South Korea. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side- 70% and Demand Side 30% • By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25% • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5% List of Companies Profiled in the Report: • SHL Medical AG (Switzerland) • Ypsomed AG (Switzerland) • Becton, Dickinson and Company (BD) (US) • Recipharm AB (Sweden) • West Pharmaceutical Services, Inc.(US) • Phillips-Medisize (US) • Halozyme, Inc. (US) • Owen Mumford Ltd. (UK) • Abbvie Inc. (US) • Eli Lilly and Company (US) • Amgen Inc. (US) • Novo Nordisk A/S (Denmark) • Jonhson & Jonhson Services Inc. (US) • Sanofi (France) • GSK plc (UK) • Gerresheimer AG (Germany) • Haselmeier (Germany) • Oval Medical Technologies Ltd. (UK) • Kaleo, Inc. (US) • Solteam Incorporation Co., Ltd. (China) • Elcam Drug Delivery Devices (Israel) • Crossject (France) • Jabil, Inc. (US) • Congruence Medical Solutions LLC (US) • Midas Pharma GMBH (Germany) Research Coverage: This research report categorizes the autoinjectors market usage (reusable and disposable), technology (manual and automatic), route of administration (intramuscular and subcutaneous), therapy area (rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, obesity and other therapy areas), Volume (upto 3ml and above 3 ml) and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the autoinjectors market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the autoinjectors market. Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the autoinjector devices and finished formulations market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The report provides insights on the following pointers: • Analysis of key drivers (rising prevalence of chronic diseases, increasing regulatory approvals for autoinjectors, high demand for biologics & biosimilars, growing adoption of self-administered medicines, government support and favorable reimbursement policies), restraints (Focus on needle-free drug delivery systems and prevalence of needle phobia ), opportunities (Impending patent expiry of biological molecules, launch of technologically-advanced autoinjectors) and Challenges (Development of autoinjectors for multiple drug viscosities) influencing the growth of the market. • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the autoinjectors market. • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the autoinjectors market • Competitive Assessment: SHL Medical AG (Switzerland), Ypsomed AG (Switzerland), Becton, Dickinson and Company (BD) (US), Abbvie Inc. (US), Eli Lilly and Company (US), Amgen Inc. (US), and Novo Nordisk A/S (Denmark) among others in the market. Table of Contents1 INTRODUCTION 381.1 STUDY OBJECTIVES 38 1.2 MARKET DEFINITION 38 1.3 INCLUSIONS & EXCLUSIONS 39 1.4 STUDY SCOPE 40 1.4.1 SEGMENTS CONSIDERED 40 1.4.2 YEARS CONSIDERED 41 1.4.3 CURRENCY CONSIDERED 41 1.5 STAKEHOLDERS 41 1.6 SUMMARY OF CHANGES 42 2 RESEARCH METHODOLOGY 43 2.1 RESEARCH DATA 43 2.1.1 RESEARCH DESIGN 43 2.1.2 SECONDARY DATA 44 2.1.2.1 Objectives of secondary research 44 2.1.3 PRIMARY DATA 44 2.1.3.1 Breakdown of primaries (supply- and demand-side participants) 45 2.1.3.2 Objectives of primary research 45 2.2 MARKET SIZE ESTIMATION OF AUTOINJECTOR DEVICES 46 2.3 MARKET SIZE ESTIMATION OF AUTOINJECTOR FINISHED FORMULATIONS 49 2.3.1 INSIGHTS FROM PRIMARY EXPERTS 51 2.3.2 TOP-DOWN APPROACH 52 2.4 MARKET GROWTH RATE PROJECTIONS 54 2.5 DATA TRIANGULATION 57 2.6 STUDY ASSUMPTIONS 58 2.7 RESEARCH LIMITATIONS 58 2.8 RISK ANALYSIS 59 3 EXECUTIVE SUMMARY 60 4 PREMIUM INSIGHTS 66 4.1 AUTOINJECTORS MARKET OVERVIEW 66 4.2 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE AND COUNTRY (2023) 67 4.3 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION AND COUNTRY (2023) 67 4.4 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2024 VS. 2030 (USD MILLION) 68 4.5 AUTOINJECTORS MARKET SHARE, BY TECHNOLOGY, 2023 68 4.6 AUTOINJECTOR DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 69 4.7 AUTOINJECTOR FINISHED FORMULATIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 70 5 MARKET OVERVIEW 71 5.1 INTRODUCTION 71 5.2 MARKET DYNAMICS 71 5.2.1 DRIVERS 72 5.2.1.1 Rising prevalence of chronic diseases 72 5.2.1.2 Increasing regulatory approvals for autoinjectors 72 5.2.1.3 High demand for biosimilars and biologics 73 5.2.1.4 Growing adoption of self-administered medicines 74 5.2.1.5 Government support and favorable reimbursement policies 74 5.2.2 RESTRAINTS 75 5.2.2.1 Focus on needle-free drug delivery systems and prevalence of needle phobia 75 5.2.3 OPPORTUNITIES 75 5.2.3.1 Impending patent expiry of biological molecules 75 5.2.3.2 Launch of technologically-advanced autoinjectors 77 5.2.4 CHALLENGES 77 5.2.4.1 Development of autoinjectors for multiple drug viscosities 77 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 78 5.4 VALUE CHAIN ANALYSIS 78 5.4.1 VALUE CHAIN ANALYSIS: AUTOINJECTOR DEVICE MANUFACTURERS (PLATFORM PROVIDERS) 78 5.4.2 VALUE CHAIN ANALYSIS: AUTOINJECTOR FINISHED FORMULATION MANUFACTURERS 80 5.5 SUPPLY CHAIN ANALYSIS 82 5.6 ECOSYSTEM ANALYSIS 83 5.6.1 AUTOINJECTOR PROVIDERS 84 5.6.2 END USERS 85 5.6.3 REGULATORY BODIES 86 5.7 REGULATORY ANALYSIS 86 5.7.1 REGULATORY LANDSCAPE 86 5.7.1.1 North America 86 5.7.1.2 Europe 87 5.7.1.3 Asia Pacific 87 5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88 5.7.2.1 North America 88 5.7.2.2 Europe 88 5.7.2.3 Asia Pacific 89 5.7.2.4 Rest of the World 90 5.8 PORTER’S FIVE FORCES ANALYSIS 90 5.8.1 INTENSITY OF COMPETITIVE RIVALRY 91 5.8.2 BARGAINING POWER OF SUPPLIERS 91 5.8.3 BARGAINING POWER OF BUYERS 92 5.8.4 THREAT OF SUBSTITUTES 92 5.8.5 THREAT OF NEW ENTRANTS 92 5.9 TRADE DATA ANALYSIS 92 5.9.1 IMPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS) 93 5.9.2 EXPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS) 93 5.10 TECHNOLOGY ANALYSIS 94 5.10.1 KEY TECHNOLOGIES 95 5.10.1.1 Injection mechanism technology 95 5.10.1.2 Electronic and connectivity solutions 95 5.10.2 ADJACENT TECHNOLOGIES 96 5.10.2.1 Wearable drug delivery devices 96 5.10.2.2 Implantable drug delivery systems 96 5.10.3 COMPLEMENTARY TECHNOLOGIES 96 5.10.3.1 Power assistance mechanisms 96 5.10.3.2 Advanced needle technology 97 5.11 PATENT ANALYSIS 97 5.11.1 METHODOLOGY 97 5.11.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE 97 5.11.3 INNOVATION AND PATENT APPLICATIONS 98 5.11.4 TOP APPLICANTS FOR PATENTS 98 5.12 INDICATIVE PRICING ANALYSIS 101 5.12.1 AVERAGE SELLING PRICE TREND, BY PRODUCT TYPE 101 5.12.2 AVERAGE SELLING PRICE TREND, BY USAGE 101 5.12.3 INDICATIVE AUTOINJECTOR FINISHED FORMULATIONS PRICING ANALYSIS, BY KEY PLAYER 102 5.12.4 INDICATIVE AUTOINJECTOR FINISHED FORMULATIONS PRICING ANALYSIS, BY REGION 103 5.13 KEY CONFERENCES AND EVENTS, 2024–2025 103 5.14 INVESTMENT AND FUNDING SCENARIO 105 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 106 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 106 5.15.1.1 Key stakeholders in buying process for autoinjector devices 106 5.15.1.2 Key stakeholders in buying process for autoinjector finished formulations 107 5.15.2 KEY BUYING CRITERIA 108 5.15.2.1 Key buying criteria for autoinjector devices 108 5.15.2.2 Key buying criteria for autoinjector finished formulations 109 5.16 IMPACT OF GENERATIVE AI ON AUTOINJECTORS MARKET 110 6 AUTOINJECTORS MARKET, BY USAGE 111 6.1 INTRODUCTION 112 6.2 DISPOSABLE AUTOINJECTORS 113 6.2.1 EASE OF USE AND REDUCED RISK OF NEEDLESTICK INJURIES TO PROPEL MARKET GROWTH 113 6.3 REUSABLE AUTOINJECTORS 118 6.3.1 COST-EFFECTIVENESS, VERSATILITY, AND SUSTAINABILITY TO FUEL MARKET GROWTH 118 7 AUTOINJECTORS MARKET, BY TECHNOLOGY 124 7.1 INTRODUCTION 125 7.2 MANUAL AUTOINJECTORS 126 7.2.1 USER-FRIENDLY DESIGN AND INCREASED PATIENT CONTROL TO AUGMENT MARKET GROWTH 126 7.3 AUTOMATIC AUTOINJECTORS 131 7.3.1 EASE OF ACCURATE DOCUMENTATION AND COMPREHENSIVE PATIENT RECORDS TO SUPPORT MARKET GROWTH 131 8 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION 137 8.1 INTRODUCTION 138 8.2 SUBCUTANEOUS ROUTE OF ADMINISTRATION 138 8.2.1 EASE OF USE, RAPID ABSORPTION, AND SUITABILITY FOR SELF-ADMINISTRATION TO AID MARKET GROWTH 138 8.3 INTRAMUSCULAR ROUTE OF ADMINISTRATION 142 8.3.1 NEED FOR PRECISE DOSE DELIVERY IN EMERGENCY CLINICAL SETTINGS TO DRIVE MARKET 142 9 AUTOINJECTORS MARKET, BY THERAPY AREA 145 9.1 INTRODUCTION 146 9.2 RHEUMATOID ARTHRITIS 147 9.2.1 HIGH DISEASE PREVALENCE AND NEED FOR FREQUENT DOSING TO DRIVE MARKET 147 9.3 DIABETES 153 9.3.1 LARGE DIABETIC POPULATION AND EASE OF ADMINISTRATION TO STIMULATE DEMAND 153 9.4 MULTIPLE SCLEROSIS 158 9.4.1 AVAILABILITY OF COST-EFFECTIVE GENERIC ORAL MULTIPLE SCLEROSIS DRUGS TO LIMIT MARKET GROWTH 158 9.5 ANAPHYLAXIS 164 9.5.1 REQUIREMENT FOR PROMPT INITIAL TREATMENT FOR PATIENTS WITH FOOD ALLERGIES TO FUEL MARKET GROWTH 164 9.6 OBESITY 169 9.6.1 INCREASING FOCUS ON WEIGHT MANAGEMENT TO BOOST MARKET GROWTH 169 9.7 OTHER THERAPY AREAS 174 10 AUTOINJECTORS MARKET, BY VOLUME 180 10.1 INTRODUCTION 181 10.2 UP TO 3ML VOLUME AUTOINJECTORS 181 10.2.1 RISING PREVALENCE OF AUTOIMMUNE DISORDERS AND LONG-TERM CHRONIC DISEASES TO PROPEL MARKET GROWTH 181 10.3 ABOVE 3ML VOLUME AUTOINJECTORS 183 10.3.1 INCREASING FOCUS ON COMPLEX TREATMENTS WITH HIGH-VISCOSITY DRUGS TO DRIVE MARKET 183 11 AUTOINJECTORS MARKET, BY END USER 184 11.1 INTRODUCTION 185 11.2 HOME CARE SETTINGS 185 11.2.1 COST-EFFECTIVENESS AND INCREASED AVAILABILITY OF HOME CARE SUPPORT SERVICES TO PROPEL MARKET GROWTH 185 11.3 HOSPITALS & CLINICS 188 11.3.1 TECHNOLOGICAL ADVANCEMENTS AND AVAILABILITY OF REAL-TIME PATIENT DATA TO SUPPORT MARKET GROWTH 188 11.4 AMBULATORY CARE SETTINGS 191 11.4.1 GROWING DEMAND FOR OUTPATIENT SERVICES TO FUEL MARKET GROWTH 191 12 AUTOINJECTORS MARKET, BY REGION 194 12.1 INTRODUCTION 195 12.2 NORTH AMERICA 196 12.2.1 US 202 12.2.1.1 US to dominate North American autoinjectors market during forecast period 202 12.2.2 CANADA 208 12.2.2.1 Rising geriatric population and increasing prevalence of food allergies to propel market growth 208 12.3 EUROPE 213 12.3.1 GERMANY 219 12.3.1.1 Favorable government initiatives and regulatory trends to aid market growth 219 12.3.2 UK 223 12.3.2.1 High prevalence of allergic conditions and increased incidence of lifestyle diseases to boost market growth 223 12.3.3 FRANCE 227 12.3.3.1 High prevalence of diabetes and favorable reimbursement policies to support market 227 12.3.4 ITALY 231 12.3.4.1 Rising healthcare expenditure and increasing geriatric population to augment market growth 231 12.3.5 SPAIN 234 12.3.5.1 Favorable reimbursement scenario and presence of universal health coverage facility to aid market growth 234 12.3.6 REST OF EUROPE 238 12.4 ASIA PACIFIC 242 12.4.1 JAPAN 247 12.4.1.1 Large geriatric population and improved healthcare infrastructure to drive market 247 12.4.2 CHINA 250 12.4.2.1 Increasing prevalence of food allergies and anaphylaxis to fuel market growth 250 12.4.3 INDIA 254 12.4.3.1 Increasing burden of diabetes and cardiovascular diseases to spur market growth 254 12.4.4 SOUTH KOREA 258 12.4.4.1 Increased regulatory approvals and strong clinical pipeline by domestic players to propel market 258 12.4.5 REST OF ASIA PACIFIC 262 12.5 LATIN AMERICA 266 12.5.1 BRAZIL 271 12.5.1.1 Rising adoption of autoinjectors and growing prevalence of chronic diseases to augment market growth 271 12.5.2 REST OF LATIN AMERICA 274 12.6 MIDDLE EAST & AFRICA 278 12.6.1 GCC COUNTRIES 283 12.6.1.1 High healthcare spending capacity and favorable regulatory scenario to drive market 283 12.6.2 REST OF MIDDLE EAST & AFRICA 287 13 COMPETITIVE LANDSCAPE 291 13.1 INTRODUCTION 291 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN 291 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AUTOINJECTORS MARKET 291 13.3 REVENUE ANALYSIS 293 13.3.1 REVENUE ANALYSIS: AUTOINJECTOR DEVICES MARKET 293 13.3.2 REVENUE ANALYSIS: AUTOINJECTOR FINISHED FORMULATIONS MARKET 294 13.4 MARKET SHARE ANALYSIS 294 13.4.1 MARKET SHARE ANALYSIS: AUTOINJECTOR DEVICES MARKET 294 13.4.2 MARKET SHARE ANALYSIS: AUTOINJECTOR FINISHED FORMULATIONS MARKET 296 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 298 13.5.1 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 298 13.5.1.1 Stars 298 13.5.1.2 Emerging leaders 298 13.5.1.3 Pervasive players 298 13.5.1.4 Participants 299 13.5.2 AUTOINJECTOR FINISHED FORMULATIONS MARKET: COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 300 13.5.2.1 Stars 300 13.5.2.2 Emerging leaders 300 13.5.2.3 Pervasive players 300 13.5.2.4 Participants 300 13.5.3 COMPANY FOOTPRINT: KEY PLAYERS, 2023 302 13.5.3.1 Company footprint 302 13.5.3.2 Region footprint 303 13.5.3.3 Usage footprint 304 13.5.3.4 Volume footprint 306 13.5.3.5 Route of administration footprint 307 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 308 13.6.1 PROGRESSIVE COMPANIES 308 13.6.2 RESPONSIVE COMPANIES 308 13.6.3 DYNAMIC COMPANIES 308 13.6.4 STARTING BLOCKS 308 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 310 13.7 COMPANY VALUATION AND FINANCIAL METRICS 311 13.7.1 FINANCIAL METRICS 311 13.7.2 COMPANY VALUATION 311 13.8 BRAND/PRODUCT COMPARISON 312 13.9 COMPETITIVE SCENARIO 313 13.9.1 PRODUCT LAUNCHES AND APPROVALS 313 13.9.2 DEALS 314 13.9.3 EXPANSIONS 315 13.10 DEVICES FOR LARGE-VOLUME FORMULATIONS 316 13.11 DEVICES FOR HIGHLY VISCOUS FORMULATIONS 317 13.12 INSIGHTS ON FUTURE AREAS OF FOCUS IN AUTOINJECTORS MARKET 319 14 COMPANY PROFILES 320 14.1 KEY PLAYERS: AUTOINJECTOR DEVICES MARKET 320 14.1.1 SHL MEDICAL AG 320 14.1.1.1 Business overview 320 14.1.1.2 Products offered 320 14.1.1.3 Recent developments 321 14.1.1.3.1 Product launches 321 14.1.1.3.2 Deals 322 14.1.1.3.3 Expansions 323 14.1.1.4 MnM view 323 14.1.1.4.1 Key strengths 323 14.1.1.4.2 Strategic choices 323 14.1.1.4.3 Weaknesses and competitive threats 323 14.1.2 YPSOMED AG 324 14.1.2.1 Business overview 324 14.1.2.2 Products offered 326 14.1.2.3 Recent developments 327 14.1.2.3.1 Product launches 327 14.1.2.3.2 Deals 327 14.1.2.3.3 Expansions 328 14.1.2.4 MnM view 328 14.1.2.4.1 Key strengths 328 14.1.2.4.2 Strategic choices 328 14.1.2.4.3 Weaknesses and competitive threats 328 14.1.3 BECTON, DICKINSON AND COMPANY (BD) 329 14.1.3.1 Business overview 329 14.1.3.2 Products offered 330 14.1.3.3 Recent developments 331 14.1.3.3.1 Deals 331 14.1.3.3.2 Other developments 331 14.1.3.4 MnM view 331 14.1.3.4.1 Key strengths 331 14.1.3.4.2 Strategic choices 331 14.1.3.4.3 Weaknesses and competitive threats 331 14.1.4 RECIPHARM AB 332 14.1.4.1 Business overview 332 14.1.4.2 Products offered 332 14.1.5 WEST PHARMACEUTICAL SERVICES, INC. 333 14.1.5.1 Business overview 333 14.1.5.2 Products offered 334 14.1.5.3 Recent developments 335 14.1.5.3.1 Expansions 335 14.1.6 PHILLIPS-MEDISIZE 336 14.1.6.1 Business overview 336 14.1.6.2 Products offered 336 14.1.6.3 Recent developments 337 14.1.6.3.1 Product launches 337 14.1.7 HALOZYME, INC. 338 14.1.7.1 Business overview 338 14.1.7.2 Products offered 340 14.1.8 OWEN MUMFORD LTD. 341 14.1.8.1 Business overview 341 14.1.8.2 Products offered 341 14.1.8.3 Recent developments 342 14.1.8.3.1 Product launches 342 14.1.8.3.2 Deals 342 14.1.8.3.3 Expansions 342 14.2 KEY PLAYERS: AUTOINJECTOR FINISHED FORMULATIONS MARKET 343 14.2.1 ABBVIE INC. 343 14.2.1.1 Business overview 343 14.2.1.2 Products offered 344 14.2.1.3 Recent developments 345 14.2.1.3.1 Product launches and approvals 345 14.2.2 ELI LILLY AND COMPANY 346 14.2.2.1 Business overview 346 14.2.2.2 Products offered 348 14.2.2.3 Recent developments 349 14.2.2.3.1 Product approvals 349 14.2.2.3.2 Deals 349 14.2.3 AMGEN INC. 350 14.2.3.1 Business overview 350 14.2.3.2 Products offered 352 14.2.3.3 Recent developments 352 14.2.3.3.1 Product launches 352 14.2.4 NOVO NORDISK A/S 353 14.2.4.1 Business overview 353 14.2.4.2 Products offered 354 14.2.4.3 Recent developments 355 14.2.4.3.1 Product approvals 355 14.2.4.3.2 Deals 355 14.2.4.3.3 Expansions 356 14.2.4.3.4 Other developments 356 14.2.5 JOHNSON & JOHNSON SERVICES, INC. 357 14.2.5.1 Business overview 357 14.2.5.2 Products offered 359 14.2.6 SANOFI 360 14.2.6.1 Business overview 360 14.2.6.2 Products offered 361 14.2.7 GSK PLC 362 14.2.7.1 Business overview 362 14.2.7.2 Products offered 363 14.2.7.3 Recent developments 364 14.2.7.3.1 Product approvals 364 14.3 OTHER PLAYERS 365 14.3.1 GERRESHEIMER AG 365 14.3.2 HASELMEIER 366 14.3.3 OVAL MEDICAL TECHNOLOGIES LTD. 367 14.3.4 KALEO, INC. 368 14.3.5 SOLTEAM INCORPORATION CO., LTD. 369 14.3.6 ELCAM DRUG DELIVERY DEVICES 370 14.3.7 CROSSJECT 371 14.3.8 JABIL INC. 371 14.3.9 CONGRUENCE MEDICAL SOLUTIONS LLC 372 14.3.10 MIDAS PHARMA GMBH 372 15 APPENDIX 373 15.1 DISCUSSION GUIDE 373 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 379 15.3 CUSTOMIZATION OPTIONS 381 15.4 RELATED REPORTS 381 15.5 AUTHOR DETAILS 382
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(その他)の最新刊レポート
MarketsandMarkets 社の最新刊レポート
本レポートと同じKEY WORD(administration)の最新刊レポート
よくあるご質問MarketsandMarkets社はどのような調査会社ですか?マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/09/20 10:26 143.76 円 160.81 円 193.57 円 |